NCT04265599

Brief Summary

The aim of the study is to characterize paraffin oil induced granulomatous disease. We will investigate pathogenesis and natural history of paraffin disease. Subsequently, through further translational studies, we intend to identify novel treatments to be tested in future randomized clinical trials.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
9mo left

Started Apr 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Apr 2019Jan 2027

Study Start

First participant enrolled

April 30, 2019

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

February 7, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 11, 2020

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2027

Last Updated

October 1, 2024

Status Verified

September 1, 2024

Enrollment Period

7.8 years

First QC Date

February 7, 2020

Last Update Submit

September 30, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of patients with concentration of ionized calcium in plasma above normal range = Hypercalcemia

    Hypercalcemia in plasma (exploratory not intervention study). yes or no and level.

    at first examination or developed during observation period until 2025

  • Number of patients with concentration of parathyroid hormone PTH in plasma below normal range

    PTH level in plasma indicator of hypercalcemia

    at first examination or developed during observation period until 2025

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

General population

You may qualify if:

  • previous intramuscular injection of paraffin or other oil

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Herlev Hospital

Copenhagen, Denmark

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples Muscle tissue

MeSH Terms

Conditions

Hypercalcemia

Condition Hierarchy (Ancestors)

Calcium Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesWater-Electrolyte Imbalance

Central Study Contacts

Ebbe Eldrup, DMSc

CONTACT

Martin Blomberg Jensen, DMSc

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator Consultant Endocrinologist MD DMSc

Study Record Dates

First Submitted

February 7, 2020

First Posted

February 11, 2020

Study Start

April 30, 2019

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

January 31, 2027

Last Updated

October 1, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations